Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer treatment. Its proprietary Boltbody ISAC platform combines tumor-targeting antibodies with immune-stimulating linker-payloads to activate the innate immune system against tumors. Key programs target tumor-associated macrophages and tumor antigens like claudin 18.2 and PD-L1. The company focuses on solid tumors, leveraging collaborations and third-party manufacturing to advance its pipeline globally.
This description was generated via AI from an annual report. Updated about 1 year ago.